Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Abemaciclib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 known ✓ | P11802 | 18/20 | 1.00 |
| ▸ | CDK6 known ✓ | Q00534 | 16/20 | 1.00 |
| ▸ | CCND3 | P30281 | 14/20 | 1.00 |
| ▸ | CDK1 | P06493 | 14/20 | 1.00 |
| ▸ | CCNA2 | P20248 | 4/20 | 1.00 |
| ▸ | CDK2 | P24941 | 3/20 | 1.00 |
| ▸ | CCND1 | P24385 | 2/20 | 1.00 |
| ▸ | CCNB1 | P14635 | 2/20 | 1.00 |
| ▸ | CCNE1 | P24864 | 2/20 | 1.00 |
| ▸ | CDK5 | Q00535 | 2/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
| ▸ | CIT | O14578 | 1/20 | 1.00 |
| ▸ | GAK | O14976 | 1/20 | 1.00 |
| ▸ | DYRK3 | O43781 | 1/20 | 1.00 |
| ▸ | CCNT1 | O60563 | 1/20 | 1.00 |
| ▸ | STK16 | O75716 | 1/20 | 1.00 |
| ▸ | CCNK | O75909 | 1/20 | 1.00 |
| ▸ | STK10 | O94804 | 1/20 | 1.00 |
| ▸ | PRKD3 | O94806 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Abemaciclib SCHEMBL29591527 | 1.00 | CDK4 (1.00) | CDK4CDK6CCND3CDK1CCNA2 | |
| Abemaciclib SCHEMBL29356350 | 1.00 | CDK4 (1.00) | CDK4CDK6CCND3CDK1CCNA2 | |
| Abemaciclib SCHEMBL29423472 | 1.00 | CDK4 (1.00) | CDK4CDK6CCND3CDK1CCNA2 | |
| SCHEMBL24021429 | 0.98 | CDK4 (0.95) | CDK4CDK6CCND3CDK1CCNA2 | |
| Abemaciclib SCHEMBL29350113 | 0.96 | CDK4 (1.00) | CDK4CDK6CCND3CDK1CCNA2 | |
| Abemaciclib SCHEMBL3447033 | 0.96 | CDK4 (1.00) | CDK4CDK6CCND3CDK1CCNA2 | |
| SCHEMBL19057207 | 0.94 | CDK6 (0.90) | CDK4CDK6CCND3CDK1CCNA2 | |
| SCHEMBL23775856 | 0.94 | CDK4 (0.88) | CDK4CDK6CCND3CDK1CCNA2 | |
| SCHEMBL2487954 | 0.94 | CDK6 (0.88) | CDK4CDK6CCND3CDK1CCNA2 | |
| SCHEMBL15252470 | 0.94 | CDK6 (0.88) | CDK4CDK6CCND3CDK1CCNA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 473 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260053761-A1 | USE OF THYROMIMETICS FOR THE TREATMENT OF CANCER | UNIV OF VERMONT AND STATE AGRICULTURAL COLLEGE (US) | 2026-02-26 | — | — | US | claimed |
| US-20240043539-A1 | METHODS OF INDUCING AN IMMUNOMODULATORY TUMOR RESPONSE | CORNELL UNIVERSITY | 2024-02-08 | — | — | US | claimed |
| WO-2024026458-A2 | USE OF GLYCOGEN METABOLISM INHIBITORS FOR THE TREATMENT OF CANCER | THE UNIVERSITY OF VERMONT (US) | 2024-02-01 | — | — | WO | claimed |
| EP-4259659-A1 | METHODS OF INDUCING AN IMMUNOMODULATORY TUMOR RESPONSE | Cornell University (US) | 2023-10-18 | — | — | EP | claimed |
| EP-3503923-B1 | COMBINATION THERAPIES FOR THE TREATMENT OF HEPATOCELLULAR CARCINOMA | EISAI R&D MAN CO LTD (JP) | 2023-10-04 | — | — | EP | claimed |
| US-20230255974-A1 | USE OF THYROMIMETICS FOR THE TREATMENT OF CANCER | UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE | 2023-08-17 | — | — | US | claimed |
| EP-4218820-A2 | COMBINATION THERAPIES FOR THE TREATMENT OF BREAST CANCER | Eisai R&D Management Co., Ltd. (JP) | 2023-08-02 | — | — | EP | claimed |
| US-20230158048-A1 | COMBINATIONS | RECURIUM IP HOLDINGS, LLC | 2023-05-25 | — | — | US | claimed |
| EP-3595725-B1 | COMBINATION THERAPIES FOR THE TREATMENT OF BREAST CANCER | EISAI R&D MAN CO LTD (JP) | 2023-05-03 | — | — | EP | claimed |
| CN-115666574-A | Combination of | 里科瑞尔姆IP控股有限责任公司 | 2023-01-31 | — | — | CN | claimed |
| WO-2017021177-A1 | PHARMACEUTICAL COMBINATIONS FOR USE IN THE TREATMENT OF CANCER | UNIVERSITAT DE BARCELONA (ES) | 2017-02-09 | — | — | WO | claimed |
| EP-3110444-A1 | COMBINATION THERAPY FOR CANCER | Eli Lilly and Company (US) | 2017-01-04 | — | — | EP | claimed |
| US-20160375030-A1 | ERK INHIBITORS | ELI LILLY AND COMPANY | 2016-12-29 | — | — | US | claimed |
| US-9526733-B1 | ERK inhibitors | ELI LILLY AND COMPANY (US) | 2016-12-27 | — | — | US | claimed |
| WO-2015130540-A1 | COMBINATION THERAPY FOR CANCER | ELI LILLY AND COMPANY (US) | 2015-09-03 | — | — | WO | claimed |
| EP-2379528-B1 | PROTEIN KINASE INHIBITORS | LILLY CO ELI (US) | 2013-09-18 | — | — | EP | claimed |
| EP-2379528-A1 | PROTEIN KINASE INHIBITORS | Eli Lilly and Company (US) | 2011-10-26 | — | — | EP | claimed |
| US-7855211-B2 | such as [5-(4-Ethyl-piperazin-1-ylmethyl)-pyridin-2-yl]-[5-fluoro-4-(7-fluoro-3-isopropyl-2-methyl-3H-benzoimidazol-5-yl)-pyrimidin-2-yl]-amine, useful in the treatment of cell proliferative diseases | ELI LILLY AND COMPANY (US) | 2010-12-21 | — | — | US | claimed |
| WO-2010075074-A1 | PROTEIN KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2010-07-01 | — | — | WO | claimed |
| US-20100160340-A1 | such as [5-(4-Ethyl-piperazin-1-ylmethyl)-pyridin-2-yl]-[5-fluoro-4-(7-fluoro-3-isopropyl-2-methyl-3H-benzoimidazol-5-yl)-pyrimidin-2-yl]-amine, useful in the treatment of cell proliferative diseases | ELI LILLY AND COMPANY | 2010-06-24 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160340-A1 | such as [5-(4-Ethyl-piperazin-1-ylmethyl)-pyridin-2-yl]-[5-fluoro-4-(7-fluoro-3-isopropyl-2-methyl-3H-benzoimidazol-5-yl)-pyrimidin-2-yl]-amine, useful in the treatment of cell proliferative diseases | MKI67, PKD1, CCNI | CDK4 26/4885CDK6 86/4885CCND3 363/4885 |
| US-20160375030-A1 | ERK INHIBITORS | MAPK4, MAPK1, MAPK3 | CDK4 120/4885CDK6 130/4885CCND3 750/4885 |
| US-20230158048-A1 | COMBINATIONS | CDK4, CDK6, CDKL4 | CDK4 1/4885CDK6 2/4885CCND3 166/4885 |
| US-20260053761-A1 | USE OF THYROMIMETICS FOR THE TREATMENT OF CANCER | THRA, THRB, TRHR | CDK4 1706/4885CDK6 1629/4885CCND3 2731/4885 |
| US-20240043539-A1 | METHODS OF INDUCING AN IMMUNOMODULATORY TUMOR RESPONSE | ICOS, IFNG, MYD88 | CDK4 2564/4885CDK6 2715/4885CCND3 3151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.